Comparative Pharmacology
Head-to-head clinical analysis: TRIAVIL 2 10 versus TRIAVIL 4 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIAVIL 2 10 versus TRIAVIL 4 10.
TRIAVIL 2-10 vs TRIAVIL 4-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRIAVIL 2-10 is a fixed-dose combination of amitriptyline (a tricyclic antidepressant) and perphenazine (a phenothiazine antipsychotic). Amitriptyline inhibits reuptake of serotonin and norepinephrine, enhancing neurotransmission. Perphenazine blocks dopamine D2 receptors, reducing dopaminergic activity in the mesolimbic pathway.
TRIAVIL 4-10 contains perphenazine, a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the limbic system, basal ganglia, and hypothalamus, and amitriptyline, a tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake.
1 tablet (perphenazine 2 mg / amitriptyline 10 mg) orally 3 to 4 times daily. Maximum: perphenazine 64 mg/day, amitriptyline 300 mg/day.
1 tablet (perphenazine 4 mg / amitriptyline 10 mg) orally 3 times daily, maximum 8 tablets daily.
None Documented
None Documented
Amitriptyline: 10-50 hours (mean 20h). Perphenazine: 8-21 hours (mean 12h). Clinically, steady state reached in 3-10 days; dose adjustments should consider accumulation.
Amitriptyline: 10-28 hours (mean 21 hours); perphenazine: 8-12 hours (mean 10 hours). Clinically, steady-state achieved in 3-5 days for amitriptyline, 2-3 days for perphenazine.
Renal excretion accounts for approximately 50-60% of total clearance for amitriptyline (metabolites) and 20-30% for perphenazine (metabolites). Biliary/fecal elimination of metabolites contributes 10-20%.
Primarily renal (about 50-70% as metabolites, <5% unchanged) and fecal (30-50% via biliary elimination).
Category C
Category C
Antidepressant-Antipsychotic Combination
Antidepressant-Antipsychotic Combination